A flexible, ROI-driven platform combining award-winning web design, deep digital marketing expertise, and decades of cybersecurity leadershipHOBOKEN, N.J., June 9, 2026 /PRNewswire/ -- In...
GUANGZHOU, China, June 9, 2026 /PRNewswire/ -- Starvia Automotive, a China-based automotive export service company, is highlighting the importance of a clear sourcing checklist...
LIVONIA, Mich., June 8, 2026 /PRNewswire/ -- Cabinetworks Group, the country's largest privately owned cabinet manufacturer, recently announced it has appointed Danielle Mikesell as...
GEORGE TOWN, Cayman Islands, June 08, 2026 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, has appointed Sachin Chawla to the new position of senior vice president, strategy and growth.
He will direct and manage the company’s business development, sales and marketing activities, while helping the CEO advance M&A and broader business growth initiatives in support of the company’s strategic growth plan.
MILAN, June 8, 2026 /PRNewswire/ -- Tethis S.p.A., a pioneering life sciences and diagnostics company, today announces the commercial launch of SmartBioSurface slides, an...
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
LOUISVILLE, Colo., June 5, 2026 /PRNewswire/ -- FlackTek™, a global leader in high-performance mixing and material processing technology, today announced the appointment of Dustin...
ALLENTOWN, Pa., June 5, 2026 /PRNewswire/ -- PPL Electric Utilities is pleased to report that, following the Pennsylvania Public Utility Commission's approval of its distribution...